Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

ResMed Inc.Trade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? ResMed Inc. trades at $196 (market cap $28.81B), while State Street SPDR S&P Biotech ETF trades at $154.42. The key difference: ResMed Inc. pays a 1.21% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.

RMDXBI
Market Cap
$28.81B
Sector
HealthBroad Market / Factor
52-Week High
$293.73$164.28
52-Week Low
$182.82$85.16
Enterprise Value
$27.99B
Dividend Yield
1.21%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI